While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > ORGANIZATION
ORGANIZATION
- JGA to Employ 3rd Party Auditor on Trial Basis to Ensure Manufacturing Compliance
March 28, 2022
- Shipment Curbs Lifted for Only 49 Products by End of 2021 after MHLW Request: FPMAJ Survey
March 25, 2022
- FPMAJ Launches Taskforce to Conduct Supply Surveys for 130 APIs
March 25, 2022
- Number of MSLs Tops 1,000 in FY2021, Up 50% in 2 Years; Lack of Talent an Obstacle to Further Growth: JAPhMed
March 22, 2022
- FPMAJ Should Take Lead to Address Drug Supply Issues: JMA Chief
March 17, 2022
- Realistic Approach Should Be Taken for Supply Chain Surveys: JPMA Economic Security Taskforce
March 15, 2022
- Japan Drug Makers Launch Digital Health Advocacy Group, Mitsubishi Tanabe Exec Serves as Head
March 15, 2022
- Switch to Original Drugs Up Nearly 5-Fold YOY in 6-Month Period from August 2021: NPhA Survey
March 15, 2022
- API Import Costs from Europe Surging amid Russian Airspace Closures
March 15, 2022
- List of 180 Needed Drugs Compiled in Europe-Led Drive to Support Ukraine
March 14, 2022
- Therapeutic Value of Kampo Medicines for COVID-19 Being Examined
March 11, 2022
- Generic/Biosimilar Association Proposes Establishing Inspector Database to Stem GMP Violations
March 9, 2022
- Apply Only Market Price-Linked Rules in Next Off-Year Revision, No Hasty Debate for Adjustment Rate: JMA Official
March 8, 2022
- Antimicrobial Use Fell 30-40% Between January 2019 and January 2021: JPA
March 7, 2022
- JMA Calls for Investigation into Increasing Cases of Off-Label Use of GLP-1 Agents
March 4, 2022
- FPMAJ Starts Survey on Industry’s Inspection Status for “Stable Supply Medicines”
March 3, 2022
- JPMA, Overseas Pharma Groups Call for Improvements in Access to COVID-19 Vaccines
March 1, 2022
- Impact of Ukraine Invasion Limited in Japan? Trader Group Says Epirubicin Is Only API Possibly Affected
February 25, 2022
- FPMAJ Begins Survey on Lifting of Shipment Restrictions
February 24, 2022
- Chuikyo Payer Rep Wants Category-Based Debate on Adjustment Rate, Prods PMP Cuts in Next Off-Year Revision
February 24, 2022
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…